Linklaters advises Cross-Border Impact Ventures (CBIV) on its participation in the Series A equity funding round of Sonio

Linklaters advised Cross-Border Impact Ventures (CBIV) on its participation in Sonio's €13 million Series A financing round to deploy its artificial intelligence solution for prenatal ultrasound.

This round of financing will enable Sonio, a French medtech specialising in women's and children's health, to continue improving its SaaS solution, kick-start its commercial development in the United States and adapt its technology for use with portable ultrasound scanners.

This financing is being led by Cross-Border Impact Ventures (CBIV) alongside the EIC Fund, historic investors Elaia, Bpifrance, OneRagtime and business angels.

Cross-Border Impact Ventures (CBIV) is an impact investor in transformative health technology companies that address the needs of women, children, and adolescents or make health systems more resilient. Through its Women’s and Children’s Health Technology Fund, CBIV primarily invests in commercial stage health technology companies with clinical evidence that have global growth, high return, and impact potential.

The Linklaters team in Paris was composed of Corporate/M&A partner Mehdi Boumedine, associate Zaid Bensebaa, Employment law partner Géric Clomes, associate Cécile Boulé, Technology, Media and Telecommunications partner Sonia Cissé, managing associate Clémentine Richard, and associate Thomas Feigean, as well as Intellectual Property partner Pauline Debré, and associate Samara Moussa.